AAN 2016

Ext-Rel Molindone Linked to Reduced Aggression in Children With ADHD

By April 21, 2016

An extended release formulation of molindone shows promise as an adjunctive treatment for refractory impulsive aggression among children administered stimulant monotherapy for ADHD.

Verapamil: No Benefit as AED Adjuvant in Reducing Seizure Frequency

By April 21, 2016

Verapamil adjuvant therapy showed no benefit versus placebo in patients with refractory epilepsy on standard antiepileptic drug (AED) treatment

Lower ARR, Higher PROs Seen After Glatiramer Acetate to DMF Switch

By April 21, 2016

DMF was associated with lower annualized relapse rates (ARR) and improvement on patient reported outcomes (PROs) in patients with relapsing multiple sclerosis (RMS) who switch to DMF following suboptimal response to glatiramer acetate (GA).

Glatiramer Acetate to Fingolimod Switch Might Reduce MS Relapse Rates

By April 21, 2016

Patients with relapsing-remitting multiple sclerosis (MS) had fewer relapses after switching from glatiramer acetate to fingolimod versus remaining on the injectable disease-modifying therapy

Peri-op Rivastigmine Patch Reduces Post-op Delirium in Elderly With Dementia Risk

By April 21, 2016

In elderly patients with cognitive dysfunction undergoing surgery for hip fracture, perioperative application of the rivastigmine patch reduced incidence postoperative delirium.

Does DMF Cut Multiple Sclerosis-Related Workplace Productivity Decline?

By April 21, 2016

Delayed-release dimethyl fumarate (DMF) is associated with better control of multiple sclerosis (MS)-associated declines in work productivity than the injectable platform therapies

Patients with RRMS Discontinue Dimethyl Fumarate Earlier Than Fingolimod

By April 21, 2016

At 12 months, patients with relapsing-remitting multiple sclerosis (MS) treated with dimethyl fumarate and fingolimod had similar rates of overall efficacy and adherence, but patients discontinued dimethyl fumigate earlier than fingolimod.

Oral Meds for MS Have Higher Adverse Effect Rates in 'Real World' vs. Clinical Trials

By April 21, 2016

In the "real world," patients with multiple sclerosis (MS) who experienced relapses while on oral medications did so at a rate comparable to that of clinical trials; however, adverse effects were higher than those observed in clinical trials.

Researchers Detail Time to Switch or Add-on for Patients on First-line AED

By April 21, 2016

Most patients on first-line anti-epileptic drug (AED) monotherapy continue initial treatment for nearly 1.5 years, according to a retrospective database study reported at the 68th AAN Annual Meeting.

Study Supports Fingolimod Use vs. iDMTs in Early Relapsing-Remitting MS

By April 21, 2016

The advantages of fingolimod over injectable disease-modifying therapies (iDMTs) in patient retention and treatment satisfaction support use of fingolimod in early relapsing-remitting multiple sclerosis (MS) in the real world.

Higher Rates of Total Migraine Freedom Observed with Intranasal vs. Oral Sumatriptan

By April 21, 2016

Treatment of acute migraine with AVP-825, an investigational Breath-Powered Bi-Directional intranasal delivery system containing sumatriptan powder 22mg, resulted in higher rates of total migraine freedom.

IncobotulinumtoxinA Injections in Hand, Forearm Improve Parkinson's Tremor

By April 21, 2016

IncobotulinumtoxinA injections customized by site and dose improved hand and forearm tremor symptoms patients with Parkinson's disease without increasing hand weakness

Levodopa-Carbidopa Intestinal Gel Well Tolerated in East Asians with Advanced PD

By April 20, 2016

Levodopa-carbidopa intestinal gel is safe and effective in Japanese, Taiwanese, and Korean patients with advanced Parkinson's disease

Durlaza Shows Sustained Antiplatelet Effects Over 24 Hours in Patients With T2DM

By April 20, 2016

Durlaza, an extended-release aspirin formulation, provides "sustained antiplatelet effects over 24 hours" in patients with type 2 diabetes mellitus (T2DM).

Clopidogrel: Antiplatelet of Choice in Smokers for Secondary Stroke Prevention?

By April 20, 2016

For both smokers and nonsmokers, adding clopidogrel to aspirin therapy is associated with a reduced risk of second stroke in the 90 days following a stroke or high-risk transient ischemic attack (TIA)—but that association is much stronger among smokers

Further Immunomodulatory Evidence for Daclizumab HYP in Relapsing-Remitting MS

By April 20, 2016

Data from patients with relapsing-remitting multiple sclerosis (MS) who received the humanized monoclonal antibody daclizumab high-yield process (HYP) "extend previous observations" on the agent's rapid pharmacodynamic effects on CD56bright natural killer (NK) cells and regulatory T-cells (Tregs) at treatment initiation, providing additional evidence for an immunomodulatory effect.

Better Parkinson's Off-Period Control Reported With Inhaled Levodopa vs. Placebo

By April 20, 2016

Parkinson's disease (PD) "off"-period symptoms control is better following administration of an inhaled levodopa powder formulation (CVT-301) than placebo.

Sodium, Other Dietary Minerals Do Not Up Risk of Multiple Sclerosis

By April 20, 2016

Dietary sodium intake is not associated with MS risk in a prospective cohort of women from the Nurses' Health Study and Nurses' Health Study II

Qudexy XR Carries Few Neurocognitive Side Effects for Refractory POS Patients

By April 20, 2016

Individual neurocognitive treatment-emergent adverse events (TEAEs) appear to be relatively infrequent among patients administered USL255 (Qudexy® XR [topiramate] extended-release capsules) for refractory partial-onset seizures (POS).

Droxidopa Effective, Safe for Symptomatic NOH Across Age Groups

By April 20, 2016

Use of the norepinephrine oral prodrug, droxidopa, for the treatment of symptomatic neurogenic orthostatic hypotension is effective and "generally well tolerated across a range of ages," including in those 75 years and older.

Deflazacort, Prednisone Improved Biomarkers of Muscle Breakdown in Boys With DMD

By April 20, 2016

Deflazacort and prednisone improved biomarkers of muscle breakdown versus placebo in boys with Duchenne muscular dystrophy, according to results of a randomized Phase 3 study reported at the 68th AAN Annual Meeting.

Women With Multiple Eclamptic Seizures More Likely to Receive AEDs

By April 20, 2016

Women with >1 eclamptic seizure were more likely to receive an AED, especially if the first seizure occurred postpartum.

Suvorexant Shown to Improve Patient Quality of Life, ISI Scores

By April 20, 2016

Suvorexant (20mg/15mg and 40mg/30mg) improves sleep for patients with insomnia and reduces the impacts of insomnia on patients' daytime functioning, as assessed using the Insomnia Severity Index questionnaire.

IV Lacosamide Effective as Acute Treatment of Status Epilepticus

By April 20, 2016

Use of lacosamide as the last antiepileptic drug (AED) a patient is administered for status epilepticus (SE) is "strongly associated with termination of status."

Valbenazine Reduces Severity of Tardive Dyskinesia in Patients With Chronic Mental Health Disorders

By April 19, 2016

Once-daily valbenazine 25 to 75mg for 6 weeks significantly reduced severity of tardive dyskinesia in patients with schizophrenia, schizoaffective disorder, depression, and bipolar disorder.

Which Antibiotics Are Most Associated With Encephalopathy?

By April 19, 2016

The "most comprehensive clinical description of antibiotic-associated encephalopathy" has found that "different antibiotics likely have varying patterns of toxicity," a review has found.

Is There a Link Between Vit D and Anti-Drug Antibody Development in MS?

By April 19, 2016

No difference in serum vitamin D levels was found between patients with multiple sclerosis (MS) and positive anti-drug antibodies (ADA) vs negative ADA in samples taken 1 year after interferon-β treatment was initiated.

Teriflunomide Associated with Reduced Disability Progression After MS Relapse

By April 19, 2016

A post-hoc analysis of pooled data from 2 clinical trials showed that teriflunomide use is associated with reduced disability progression after MS relapse, compared to placebo. The findings were presented at the 68th AAN Annual Meeting.

For Relapsing-Remitting MS, Alemtuzumab Provides Durable 5-Year Efficacy

By April 19, 2016

Patients with active relapsing-remitting multiple sclerosis (MS) who had an inadequate response to one or more prior therapies at baseline showed durable improvement in clinical efficacy with alemtuzumab at 5 years.

Topiramate May Raise Risk of Psychiatric Comorbidities in Patients With Epilepsy

By April 19, 2016

Topiramate may increase risk of developing psychiatric comorbidities in people with epilepsy when compared with valproate, carbamazepine, lamotrigine, and levetiracetam, all of which may lower risk, according to study results reported at the 68th AAN Annual Meeting.